Cullinan's T-cell engager CLN-978 cleared by FDA to begin clinical studies for B-cell NHL
Jan. 25, 2023
The FDA has cleared Cullinan Oncology Inc.'s IND application for CLN-978, a CD19/CD3 T-cell engaging antibody construct with a human serum albumin (HSA) binding domain to increase serum half-life.
